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Bone marrow-derived mesenchymal stromal cells (MSCs) hold promise for autologous treatment of neuropathologies. Intranasal
delivery is relatively noninvasive and has recently been reported to result in transport of MSCs to the brain. However, the ability of
MSCs to migrate from nasal passages to sites of neuropathology and ultimately survive has not been fully examined. In this paper,
we harvested MSCs from transgenic mice expressing enhanced green ﬂuorescent protein (cells hereafter referred to as MSC-EGFP)
and delivered them intranasally to wild-type mice sustaining mechanical lesions in the striatum. Using ﬂuorescent, colorimetric,
and ultrastructural detection methods, GFP-expressing cells were undetectable in the brain from 3 hours to 2 months after MSC
delivery. However, bright autoﬂuorescence that strongly resembled emission from GFP was observed in the olfactory bulb and
striatum of lesioned control and MSC-EGFP-treated mice. In a control experiment, we directly implanted MSC-EGFPs into the
mouse striatum and detected robust GFP expression 1 and 7 days after implantation. These ﬁndings suggest that—under our con-
ditions—intranasally delivered MSC-EGFPs do not survive or migrate in the brain. Furthermore, our observations highlight the
necessity of including appropriate controls when working with GFP as a cellular marker.
1.Introduction
Bone marrow-derived mesenchymal stromal cells (MSCs)
are self-renewing precursors that—under some circumstan-
ces—have been shown to diﬀerentiate into cells of mesen-
chymallineagessuchasbone,cartilage,muscle,andfat[1,2].
In addition, it has been reported both in vitro and in vivo
that MSCs can be precursors of cells in neural lineages [3–6],
although there is continuing controversy over these ﬁndings
[7,8].AnumberofstudieshavedemonstratedthatMSCscan
engraft and survive for limited periods after direct implanta-
tion into the striatum [9–11]. However, controversy remains
as to whether MSCs given in vivo have the intrinsic capacity
to diﬀerentiate into neural cells, migrate within the brain,
and survive for extended periods [12, 13]. Regardless, MSCs
are widely considered a potential source for the autologous
treatment of a range of neurodegenerative or neurological
disorders via delivery of growth factors or by replacement of
damaged cells [14–16].
Invasiveorineﬃcientroutesaretypicallyusedtoadmini-
ster MSCs (i.e., intracerebroventricular, intracerebral, intra-
peritoneal, or intravascular), which would complicate clini-
cal use. Intranasal administration is an attractive option for
delivering MSCs to the brain because it is relatively nonin-
vasive, and the olfactory region is a unique interface between
theexternalenvironmentandthecentralnervoussystemthat
bypasses the blood-brain barrier [17, 18]. Intranasal admin-
istration of small peptides, drugs, and viruses results in pas-
sage of these substances to the brain [18–23], although larger2 Stem Cells International
viral particles do not appear to migrate further than the
olfactory bulb [22, 23]. Although the eﬃciency of the intra-
nasal route may be low, the potential advantages over more
invasive techniques warrant further study.
Recently, it has been reported that intranasal delivery of
ﬂuorescently labeled MSCs to mice resulted in migration of
some cells to the brain [24, 25] and attenuation of 6-OHDA-
mediated motor impairments in a model of Parkinson’s dis-
ease [26]. The current study was designed to replicate the
above ﬁndings and to test the hypothesis that intranasal deli-
very of MSCs to mice that sustained a striatal lesion would
result in migration and engraftment of cells from the olfac-
tory epithelium to the lesion site.
One issue that has hampered eﬀorts to study the ther-
apeutic potential of MSCs within the brain is the limited
ability to track MSCs and diﬀerentiate them from endoge-
nous cells. We used MSCs isolated from transgenic mice ex-
pressing EGFP under control of the CAG promoter, as has
been described previously [3, 27]. Because the presence of
endogenous tissue autoﬂuorescence can make it diﬃcult to
accurately detect relatively rare events of stem cell migration
and survival in the brain, the inclusion of appropriate con-
trols has been strongly recommended [28, 29], and we put
special emphasis on discriminating between nonspeciﬁc and
GFP-speciﬁc signals in brain tissue. Finally, we performed
a control experiment in which we implanted MSCs directly
into the striatum to verify that MSCs isolated and cultured
under our conditions could survive in brain, as previously
described [9–11].
2.MaterialsandMethods
2.1. Generation of an EGFP-Expressing Mesenchymal Stromal
Cell (MSC) Line. For the generation of an EGFP-expressing
MSC line (MSC-EGFP) bone marrow cells (BMC) were har-
vested from the femurs of 7-week-old male transgenic mice
(N = 6 mice) expressing enhanced GFP (C57BL/6-Tg(CAG-
EGFP)1Osb/J; The Jackson Laboratories, Bar Harbor, MN)
according to published protocols [6, 27, 30] using Dulbecco’s
Modiﬁed Eagle Medium/High Glucose (DMEM/HG media;
Invitrogen) supplemented with 2mM L-glutamine, and 15%
fetal bovine serum (FBS). To separate MSCs from the total
BMC population, media was changed at 3hr and then every
8 hr up to 72 hr after initial plating of BMC suspension.
At each media change, nonadherent cells were removed,
leaving adherent MSCs [30]. Following isolation of MSCs,
a clonal cell population was derived as previously described
[6], except that the cells were propagated for 3 weeks in
DMEM/low glucose (DMEM/LG; Sigma) with 2% FBS
(Hyclone), 1nM dexamethasone (Sigma), 2.5ng/mL bFGF,
10ng/mL mEGF, and 10ng/mL mLIF (as in [27]).
2.2. Flow Cytometry (FCM). Cultured BMCs and MSC-
EGFPs were trypsinized, washed in PBS, and subjected to
standard FCM analysis using the Mouse Multipotent Mes-
enchymal Stromal Cell Marker Antibody Panel (R&D Sys-
tems; catalog #SC018) according to the conditions provided
by the manufacturer with 568-labeled Alexa Fluor secondary
antibodies (Invitrogen) and an LSR Fortessa FACS machine
Table 1: Treatment groups.
Numbered mice/group
Pretreatment MSC Delivery route 3hr 1d 7d 2mos
Mechanical
lesion
V e h I N 333 3
MSC-EGFP IN 3 3 2 2
No lesion
Veh IN 2
MSC-EGFP IN 2
Veh IS 3 3
MSC-EGFP IS 3 3
Total mice: 38.
Abbreviations: IN: intranasal; IS: intrastriatal.
(BD Biosciences). Data were analyzed using FlowJo software
version 8.7.3 (TreeStar).
2.3.Mice. Atotal of38 C57Bl/6J mice(Jackson Laboratories,
Bar Harbor, ME) were used in this study. Mice weighed 25–
27gatthetimeofthestudy(approximately10–12weeksold)
and were maintained on a 12-h light/dark (7:00 AM to 7:00
PM) cycle with ad libitum access to food and water except
during testing. Experiments were conducted in accordance
with the 1996 National Institute of Health Guide of the Care
and Use of Laboratory Animals and McLean Hospital policies.
See Table 1 for a breakdown of the number of mice per treat-
ment group.
2.4. Intranasal MSC-EGFP Delivery. A total of 26 mice
were used for studies of intranasal MSC-EGFP delivery (see
Table 1). A surgical (sham) lesion of the dorsal striatum was
performed on mice (N = 22) 3 weeks prior to intranasal
delivery of MSC-EGFPs. This time frame was used because
our long-term goal was to determine whether intranasal ad-
ministration of MSCs can rescue neurochemical and behav-
ioral deﬁcits induced by 6-hydroxydopamine (6-OHDA) le-
sions of the dopaminergic system, which take approximately
3w e e k st oo c c u r[ 31]. In the current study, which did not
involve 6-OHDA, mice were anesthetized with an intraperi-
toneal (IP) injection of a ketamine HCl (100mg/kg) and
xylazine HCl (15mg/kg) mixture (Sigma). Mice were immo-
bilized in a stereotaxic instrument and received 2 unilateral
microinjections of 0.01% ascorbic acid (N = 22 mice; 2
injections × 1.5μL/injection) into the left striatum. Ascorbic
acid was used because it is a common vehicle for 6-OHDA.
Injection coordinates were 1.0mm anterior to Bregma,
1.4mm lateral to midline, and 3.3mm ventral to the skull
surface; 0.1mm anterior to Bregma, 1.6mm lateral to mid-
line, and 3.3mm ventral to the skull surface [32]. Microin-
jections were done at a rate of 0.35μL/min with a 33-gauge
injector needle (Plastics One, Roanoke, VA) attached by
polyethylene (PE) tubing to a 10μL Hamilton syringe in
a syringe pump. Each 4.3-min infusion was followed by a
3 - m i nw a i tp e r i o dt oa l l o wf o rd i ﬀusion before removing the
injector needle.
Three weeks after lesion, recipient mice received either
intranasal vehicle or MSC-EGFPs. An additional 4, unlesion-
ed, mice also received intranasal MSCs (see Table 1). Mice
were lightly anesthetized with an IP injection of a ketamineStem Cells International 3
HCl (50mg/kg) and xylazine HCl (7.5mg/kg) mixture
(Sigma). Using a standard gel-loading pipette tip, 10μLo f
sterile phosphate buﬀered saline (PBS) or PBS containing
25,000 MSC-EGFPs was administered dropwise into each of
the nares, resulting in delivery of 50,000 MSC-EGFPs per
mouse. PBS was chosen as the vehicle based on previously
published reports [24, 26]. Mice were sacriﬁced 3h, 1d, 7d,
or 2 months after MSC-EGFP delivery.
2.5. Intrastriatal MSC-EGFP Delivery. Mice (N = 12) were
anesthetized with an intraperitoneal (ip.) injection of a keta-
mine HCl (100mg/kg) and xylazine HCl (15mg/kg) mixture
(Sigma). Mice were immobilized in a stereotaxic instrument
and received 1 unilateral microinjection (2μLa t0 . 2μL/min)
of 75,000 MSC-EGFPs in culture media (DMEM/F12 con-
taining 0.66% glucose, 0.125% NaHCO3, and 0.0056M
HEPES with 0.05% DNAse) or media alone, as in Moloney
et al. [11] using a 26-gauge Hamilton syringe. Injection co-
ordinates were: 1.0mm anterior to Bregma, 1.4mm lateral to
midline, and 3.3mm ventral to the skull surface. Mice were
sacriﬁced 1 or 7d after MSC-EGFP delivery.
2.6. Immunohistochemistry. Mice were sacriﬁced at various
timepoints after MSC-EGFP delivery by sodium pentobarbi-
taloverdose(130mg/kg,IP)andweretranscardiallyperfused
with 10% formalin in phosphate buﬀer (Fisher). Brains were
kept in formalin at 4◦C overnight and then saturated in
30% sucrose in phosphate buﬀered saline for 3 days until
sectioningonaVibratometissueprocessor(Series1000,TPI,
St. Louis, MO). Sagittal or coronal sections (30μm) were
cut through the entire brain and collected in 10% formalin.
For ﬂuorescent detection of MSC-EGFPs, tissue sections
were either mounted directly to view endogenous GFP, or
processed for immunohistochemistry.
Tissue sections were washed 3 × 5min in diluting buﬀer
(2% bovine serum albumin, 0.9% NaCl, 0.4% Tween 20
and 1% normal goat or horse serum in 0.1M phosphate
buﬀered saline PBS) then blocked with 20% normal goat or
horse serum in 0.1M PBS for 30min. Primary antibodies
were diluted in diluting buﬀer and sections were incubated
overnight at room temperature. For ﬂuorescence imaging,
some sections were counterstained with 1μg/mL DAPI (4 6-
diamidino-2-phenylindole; Sigma). Primary antibodies used
were GFP (polyclonal made in rabbit, 1:2000, Abcam) and
glial ﬁbrillary acidic protein (GFAP, polyclonal made in
rabbit, 1:250, DAKO Corporation, Carpinteria, CA). Secon-
dary antibodies included Alexa Fluor 488 ﬂuorophore made
in goat (anti-rabbit, 1:1000, Invitrogen, Carlsbad, CA) and
biotinylated anti-rabbit IgG (1:1000) followed by strepta-
vidin-conjugatedAlexa568ﬂuorophore(1:200,Invitrogen).
In an attempt to quench autoﬂuorescence, some tissue sec-
tions were pretreated with 0.3% Sudan Black in 0.1M PBS
(Sigma) 5min prior to immunohistochemistry [(see Supple-
mentary Figure 2 in supplementary material which is avail-
able online at doi:10.4061.2011.586586)].
Tissue sections adjacent to those used for ﬂuorescence
were processed for nonﬂuorescent, colorimetric detection of
GFP using an avidin-biotin system (Vectastain ABC kit;
Vector) with diaminobenzidine (DAB; Vector) as the chro-
magen. GFP polyclonal antibody (Abcam) made in rabbit
was used at 1:2000 and biotinylated anti-rabbit IgG (Vector
Laboratories, Burlingam, CA) was used at 1:1000.
Sections were visualized and captured with an upright
Zeiss Z1 microscope connected to a digital camera (Zeiss
AxioCam HRc). Images were processed using AxioVision
software (Zeiss) and Photoshop (version 8.0; Adobe Systems
Incorporated, San Jose, CA). Negative controls for immuno-
histochemical staining were performed by omitting the pri-
mary antibody. Also, brain regions contralateral to the lesion
were examined and served as internal controls.
For ultrastructural analysis of MSC-EGFPs at the lesion
sites, tissue sections processed for GFP IHC with DAB were
postﬁxedwith1%osmiumtetroxide(OsO4)insodiumpho-
sphate buﬀer, pH 7.2, dehydrated through graded ethanols,
and ﬂat embedded in Embed-812 between ACLAR sheets
(EMS, Fort Washington PA). Appropriate regions of the tis-
sue were attached to epon blanks and ultrathin sections were
cut using a Reichert-Jung ultra-microtome, mounted on
Cu grids and lightly stained with aqueous uranyl acetate
(10min) and Reynold’s lead citrate (4min). Sections were
examined using a Jeol 1200EX transmission electron micro-
scope (JEOL, Tokyo, Japan) with an AMT Digital Imaging
System (Advanced Microscopy Techniques Corp., Danvers
MA).
3. Results
3.1. Phenotypic Proﬁle of MSC-EGFPs. Using FCM and the
Mouse Multipotent Mesenchymal Stromal Cell Marker Anti-
body Panel, we phenotyped the MSC-EGFP line (passage
4) and compared it to normal C57BL/6 BMCs three weeks
after harvest and growth in serum-containing mitogen-free
conditions (3 passages; Figure 1(a)). The total population of
BMCssegregatedintotwofractions:largecells,whichweakly
expressed Sca-1, but strongly expressed CD29 and CD44,
and which were negative for CD106, CD105, CD73, CD11b,
and CD45, and small cells, which exhibited no expression of
any of the markers analyzed. The MSC-EGFPs were strongly
positiveforSca-1,CD29,andCD44(similartothelargefrac-
tion of BMCs) while negative for CD106, CD105, CD73,
CD11b, and CD45.
3.2. Detection of EGFP in MSCs. MSCs were used at passage
4andthepresenceofGFPwasconﬁrmedintheculturedcells
prior to delivery to the animals (see Figures 1(b)–1(d)). The
MSC-EGFPs had a ﬂattened appearance and a ﬁbroblast-
like shape (Figure 1(b)). These cells exhibited bright green
ﬂuorescence (Figure 1(c)) when visualized with a GFP band-
pass ﬁlter, but did not ﬂuoresce when visualized with a Texas
Red bandpass ﬁlter (Figure 1(d)), conﬁrming that the green
ﬂuorescence was due to GFP expression and not autoﬂuores-
cence. Thus, immediately before intranasal administration,
M S C - E G F P sw e r ev i a b l ea n de x p r e s s e dG F P .
3.3. Detection of MSC-EGFPs Delivered Intranasally. Sagittal
orcoronalbrainsectionsfromstriatallylesionedmicetreated
intranasally with either saline or MSC-EGFP were exam-
ined for the presence of GFP-positive cells by ﬂuorescence4 Stem Cells International
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Figure 1: Phenotypic proﬁling of cultured BMCs and MSC-EGFPs. (a) BMCs cultured for three weeks in serum-containing mitogen-
free conditions and mitogen-activated MSC-EGFPs at passage 18 were analyzed by Flow cytometry (FCM) using the Mouse Multipotent
Mesenchymal Stromal Cell Marker Antibody Panel (R&D Systems). Shown are the positively staining markers Sca-1, CD29, and CD44, and
an example of negative staining for the hematopoietic marker CD45. ((b), (c), (d)) Undiﬀerentiated mesenchymal stromal cells derived from
adult EGFP transgenic mice (MSC-EGFP) appear as large, ﬂat ﬁbroblast-like cells that express high levels of the enhanced green ﬂuorescent
protein reporter, EGFP. MSC-EGFPs are shown under (b) phase contrast and (c) GFP bandpass ﬁlter, demonstrating eGFP expression and
(d) Texas Red bandpass ﬁlter, demonstrating lack of autoﬂuorescence.
microscopy. Three hours after MSC-EGFP delivery, ﬂuores-
cent cell-like structures were visible within the glomerular
layer of the OB, but they did not resemble the MSC-EGFPs
seen in culture. This ﬂuorescence in OB was detectable at
similar intensity levels when viewed under multiple emission
ﬁlters, suggesting autoﬂuorescence. One possibility was that
GFP expression was low in the OB, so in an attempt to
amplify GFP signal, we used an antibody to GFP for sub-
sequent observations. Under these conditions, similar ﬂuo-
rescent cell-like structures were visible within the glomerularStem Cells International 5
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40x
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Figure 2: Autoﬂuorescence in the olfactory bulb (OB) after intranasal delivery of MSC-EGFPs to mice with prior mechanical lesions in
striatum. Fluorescent structures are observed within the glomerular layer of the OB at 3 hours and 7 days after intranasal administration of
MSC-EGFPs (a), (b) or saline (c), (d). Higher magniﬁcation images of the OB at 3 hours ((a , c) inset) and 7 days ((b , d) inset) imaged with
both the GFP and Texas Red bandpass ﬁlters show a one-to-one correlation between the number and intensity of stained structures.
and—to a lesser extent—the external plexiform layers of the
OB at 3hr, 1 and 7 days, and 2 months after MSC-EGFP
delivery to mice with striatal lesions when viewed with a
GFP bandpass ﬁlter (for 3hr and 7d, see Figures 2(a) and
2(b)).However,ﬂuorescenceofidenticalintensityandspatial
distribution was observed with all ﬁlters, including a Texas
Red bandpass ﬁlter (Figures 2(a )a n d2(b )). Similar ﬂuores-
cent structures were visible within the glomerular cell layer
in striatally lesioned mice that received intranasal vehicle
(Figures 2(c) and 2(d)). No ﬂuorescence above background
was observed in deeper layers of the OB or along established
routes of migration such as the olfactory-neuronal pathway
[18].
Robust autoﬂuorescence was also observed in the stria-
tum along the trajectory of the injector needle used to make
the mechanical striatal lesions. Regardless of intranasal treat-
ment (MSC-EGFPs or saline), the autoﬂuorescence looked
similar. At day 7 after intranasal treatment, the ﬂuorescence6 Stem Cells International
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Figure 3: Autoﬂuorescence in the striatum of mice that received mechanical striatal lesions followed 3 weeks later by intranasal saline or
MSC-EGFPs. Bright particulate ﬂuorescence is observed at the termination of the lesion injector needle at 7 days after intranasal delivery of
MSC-EGFPs(a,c,e)orsaline(b,d,f).ThenumberofstructuresandintensityofﬂuorescenceisthesameontheGFPandTexasRedbandpass
ﬁlters (c  and d ).
had an “explosive,” particulate appearance (Figures 3(a) and
3(b)) that was of equal intensity under both red and
green ﬂuorescent ﬁlters (Figures 3(c)–3(d )). At higher
magniﬁcation, some of the ﬂuorescent bodies appear-
ed loosely associated with DAPI-stained nuclei, although
they had a punctate appearance not seen in healthy tissue
(Figures 3(e)–3(f )). At 2 months after intranasal treat-
ment, the autoﬂuorescence had dissipated signiﬁcantly from
around the needle track, but it was still indistinguishable
between MSC-EGFP- and saline-treated mice (Supp. Fig-
ures 1(A) and 1(B)), with similar intensities under the red
and green ﬁlters (Supp. Figures 1(C) and 1(D)). Some of the
ﬂuorescent bodies appeared to be associated with DAPI-
stained nuclei (Supp. Figures 1(E) and 1(F)). Importantly,
the ﬂuorescent structures were diﬃcult to deﬁne, and it was
not possible to clearly focus on them, similar to what is des-
cribed for lipofuscin autoﬂuorescence [33].
Several methods exist to reduce (quench) autoﬂuores-
cence in brain (see [33]). Sudan Black is an opaque dye
that is eﬀective at obscuring lipofuscin without interacting
with it at the chemical level. It has been shown to reduce aut-
oﬂuorescenceatconcentrationsthathaveminimalimpacton
immunohistochemicalstaining.Wepretreatedasubsetoftis-
suesectionswithSudanBlack(0.3%)andexaminedGFPand
tyrosine hydroxylase (TH) staining in the striatum. Sudan
Black pretreatment globally reduced ﬂuorescence inten-
sity,butdidnoteliminateautoﬂuorescenceatconcentrations
that still allowed for detection of TH (Supp. Figure 2).
To determine whether the autoﬂuorescence observed in
our tissue was associated with a glial response, we colabeled
tissue from mice sacriﬁced 2 months after intranasal MSC
administration with anti-GFP and anti-GFAP antibodies.
Autoﬂuorescent bodies in the side of the striatum ipsilateral
to the lesion were surrounded by strong GFAP expression,
which was localized along the injector needle trajectory
(Figures 4(a) and 4(b)). In contrast, low, background levels
of GFAP staining and autoﬂuorescence were observed on the
side of the striatum contralateral to the lesion (Figure 4(c)).Stem Cells International 7
40x
20x
(a) (b) (c)
Figure 4: Double label immunohistochemistry shows close association between glial ﬁbrillary acidic protein (GFAP) and autoﬂuorescence
along the injector needle track in the striatum, 2 months after intranasal delivery of MSC-EGFPs. (a) Green autoﬂuorescence along needle
track.Inset,higher-magniﬁcationimagefrom(a).(b)GFAP(red)expressionisstrongalongtheneedletrack.(c)SubstantiallylessGFAP,and
no green autoﬂuorescence, is detected in the contralateral striatal hemisphere.
3.4. Detection of EGFP In Vivo: Light Microscopy. To circum-
vent the issue of autoﬂuorescence seen in ﬂuorescence mi-
croscopy, we performed additional immunohistochem-
istry on adjacent tissue sections from mice treated intra-
nasally with MSC-EGFPs using the same GFP polyclonal pri-
mary antibody and a biotinylated secondary antibody that
can be detected with an avidin-biotinylated peroxidase enzy-
me complex reaction. Tissue sections were counterstained
with cresyl violet. In sections from mice treated with either
intranasal saline or MSC-EGFPs, a dense, DAB-positive clus-
terwasobservedatthedistalendoftheinjectorneedletracks
in the striatum (not shown). At higher magniﬁcation, this
DAB-positive cluster appeared punctate and was not clearly
associated with cresyl violet stained nuclei (Figure 5(a)). In
addition, it was not possible to focus on these structures,
which had an amorphous appearance.
3.5. Ultrastructural Analysis of DAB-Positive Structures in the
Striatum. To determine whether GFP-speciﬁc staining, and
by implication MSC-EGFPs, was present amid the nonspe-
ciﬁc and amorphous structures observed in the striatum
with both ﬂuorescence and light microscopy, we performed
electron microscopy on DAB-stained striatal tissue from
mice that received intranasal MSC-EGFPs either 7 days or
2monthspriortosacriﬁce.Weobservedmanycell-likestruc-
tures that were darker than surrounding tissue and cells
(Figures 5(b)–5(d)). A number of these cells appeared to be
a ta d v a n c e ds t a g e so fd e g r a d a t i o n :c e l l u l a rs t r u c t u r e ss u c ha s
mitochondria, endoplasmic reticulum, and Golgi were not
detectable, the cytoplasm was ﬁlled with inclusion bodies,
lipofuscin,andlysozymes,andthenucleus,whenobservable,
was relatively small and eccentric (Figure 5(c)). A diﬀerent
population of shrunken, electron dense structures with dark,
pyknotic chromatin were also observed (Figure 5(d)). Based
on this morphology, it is likely that these structures are nec-
rotic cells [34]. Interestingly, in these smaller necrotic cells,
organelles such as mitochondria, endoplasmic reticulum,
and Golgi apparati could still be detected. For comparison, a
healthy neuronal cell can also be seen in the lower right cor-
ner of Figure 5(b)(B ), in which normal cellular structures
arevisible,thenucleusisintactandcentrallylocatedwithdif-
fuse and light chromatin, and there is no evidence of inclu-
sion bodies.
3.6. Detection of MSC-EGFPs Delivered Intrastriatally. To
verify that MSC-EGFPs cultured under our conditions were
able to survive in brain, as in previous reports [9–11], we
performed a control experiment in which MSC-EGFPs were
implanted directly into the striatum of recipient mice. One
day after intrastriatal injection, GFP-speciﬁc ﬂuorescence
was detected in the striatum in a cellular graft concentrated
around the injection site (Figures 6(a), 6(b), and 6(c)). Visu-
alizationoftheMSC-EGFPgraftunderaTexasRedbandpass
ﬁlter showed no detectable ﬂuorescence (Figure 6(c )). No
MSC-EGFPs were detected outside of the graft area, sug-
gesting a lack of migration at this time point. Seven days
afterintrastriatalinjection,GFP-speciﬁcﬂuorescencewasde-
tected in the striatum in a cellular graft concentrated
around the injection site similar to that observed at 1 day
(Figures 6(e), 6(f), and 6(g)). In contrast, visualization of the
MSC-EGFP graft under a Texas Red bandpass ﬁlter showed
ad i ﬀuse, low level of ﬂuorescence interspersed with bright
puncta(Figure 6(g )).Thissuggeststhepresenceofautoﬂuo-
rescent inclusion bodies that may be associated with dying
MSC-EGFPs. Olfactory bulb tissue was also examined at 1
and 7d after intrastriatal implantation. Fluorescent cell-like
structures were visible within the glomerular layer of the OB
(Figures 6(d) and 6(h)). However, ﬂuorescence of identical8 Stem Cells International
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Figure 5: Ultrastructural analysis of striatal tissue from mice intranasally administered MSC-EGFPs. (a) Representative example of light
microscopy image of DAB-stained tissue in striatum. (b) Characteristic structure observed in striatum of mice at 7 days after MSC-
EGFP treatment. Darkened cell-like structures have few if any discernable organelles but are full of inclusion bodies, lipofuscin, and other
degenerated products. A healthy nucleus and cell can be seen in the lower right portion of the panel (B ). 2 months after MSC-EGFP
treatment, similar darkened structures were detected (c) as well as darkened cells with pyknotic nuclei, shrunken cytoplasm, and vacuoles
(c) and (d). Scale bar is 2μm.
intensityandspatialdistributionwasobservedwithallﬁlters,
including a Texas Red bandpass ﬁlter (Figures 6(d )a n d
6(h )), suggesting the presence of endogenous autoﬂuores-
cence in the OB. Thus there was no detectable migration of
MSCs from the injection site following 7-day survival, but
there was evidence of MSC loss at the injection site at this
time.
4. Discussion
In this study, we tested whether MSCs isolated from bone
marrow of EGFP transgenic mice and delivered intranasally
wouldentertheOB,survive,andmigrateovertimetoadistal
lesion site in the striatum. We found no evidence of viable
MSC-EGFPsinanyregionofthebrainat3hours,1or7days,
or 2 months after intranasal administration. The lack of
MSC-EGFPs was not due to an intrinsic inability of the cells
to engraft or survive in vivo, because MSC-EGFPs implanted
directly in the striatum survived for at least 7 days. Notably,
in our search for viable MSC-EGFPs in brain, we observed
high levels of autoﬂuorescence in both the intact OB and in
the lesioned striatum several weeks after a mechanical lesion.
We think it is conceivable that this autoﬂuorescence couldStem Cells International 9
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Figure 6: Detection of MSC-EGFPs after intrastriatal delivery. (a) 1d after implantation, endogenous eGFP ﬂuorescence from MSCs is
found proximal to the injector needle track. Tissue counterstained with DAPI. (b) At higher magniﬁcation (40x), ﬁbroblast-like structure of
implanted MSC-EGFPs can be seen. Fluorescence is detected on GFP (c), but not Texas Red (c ) emission ﬁlters. In the OB, autoﬂuorescence
is detected on both the GFP (d) and Texas Red (d ) emission ﬁlters. (e) 7d after implantation, endogenous eGFP ﬂuorescence from MSCs
is found around the injector needle track. Tissue counterstained with DAPI. (f) At higher magniﬁcation (40x), implanted MSC-EGFPs can
be seen. Fluorescence is detected on GFP (g), and Texas Red (g ) emission ﬁlters, although there is no overlap with GFP signal. In the OB,
autoﬂuorescence is detected on both the GFP (h) and Texas Red (h ) emission ﬁlters. Abbreviations: cc: corpus callosum; lv: lateral ventricle.
be mistaken for the presence of EGFP-labeled MSCs. This is
consistent with past studies demonstrating the diﬃculty in
discriminating between true GFP signal and artifact, which
occurs, at least in part, because autoﬂuorescence emission
spectra partially overlap the emission of GFP [28, 29, 33, 35].
Recently, it has been reported that intranasal delivery of
ﬂuorescently labeled rat MSCs to mice resulted in migration
of a remarkable number of cells to olfactory bulb, cortical,
hippocampal, striatal, and thalamic brain structures within
hours of cell administration [24–26] .T h e r ea r es e v e r a lp o s -
sible reasons for the apparent discrepancy with our study.
First,weadministered6-foldfewercellsthanDanielyanetal.,
raising the possibility that the number of starting MSC-
EGFPs was not suﬃcient to yield signiﬁcant and detectable10 Stem Cells International
numbers of MSCs in the brain. However, this seems unlikely
given that between 500–2000 MSCs were detectable in the
OB within the ﬁrst 4hr after intranasal administration in
the Danielyan studies [24, 26], and a 6-fold decrease in this
number of OB MSCs would still be detectable with the
methods described here. Second, the use of GFP in our study
could have reduced the capacity of the MSCs for survival.
However,ithasrecentlybeenshownthatthepresenceofGFP
in MSCs does not adversely eﬀect the survival of stem cells
in the brain [11]. Third, it is possible that the mechanical
striatal lesion triggered a tissue response that led to rejection
of the MSCs. Mechanical lesions are known to induce an
inﬂammatory response, and we found that more than 2
months after intrastriatal ascorbic acid administration, there
was still robust GFAP expression around the injector needle
track. Although we do not characterize what produces this
immuneresponse,itislikelythatthechemicalmilieuaround
the damaged tissue includes cytokines, growth factors, and
other potential chemical signals that could attract—or
repel—the MSC-EGFPs. This is consistent with prior work
showingthattheinﬂammatoryresponsetointrastriatalMSC
delivery itself is suﬃcient to reject the engrafted MSCs over
time [10, 36]. However, Coyne et al. show that MSCs sur-
vive for at least a week before rejection whereas we never saw
evidence of surviving MSCs after intranasal delivery. We
believe the most likely explanation is that the MSC-EGFPs
simply fail to pass through the olfactory mucosa and epithe-
lium, and are thus never exposed to the brain itself.
Although we detected no MSCs in the brain after intra-
nasal delivery, there was abundant ﬂuorescence. True ﬂuore-
scence signal from GFP has a narrower emission spectrum
than autoﬂuorescence. Thus, true GFP emissions will not be
detected with longer wavelength (>550nm) bandpass ﬁlters
(i.e., Texas Red). In our studies, a GFP-speciﬁc signal was
presentinMSC-EGFPsincultureandinthestriatumofmice
that received intrastriatal infusions of cells, since ﬂuorescent
signalwasdetectedonlyunderthegreen(GFPbandpass)and
not under the red (Texas Red) emission ﬁlters. However, in
miceadministeredMSC-EGFPsintranasally,noGFP-speciﬁc
signal could be discriminated from autoﬂuorescence. Every
structure that was ﬂuorescent under the GFP bandpass ﬁlter
was detected with equal intensity under the Texas Red ﬁlter.
These types of negative controls are often not reported in
the literature, despite several papers calling for appropriate
controls [28, 29, 35, 37].
The autoﬂuorescence observed in the striatum in our
study is strongly associated with the mechanical lesion site
and GFAP expression and is most likely due to damaged
tissue products andlipofuscin, whichautoﬂuorescesat wave-
lengthssimilartoGFP[35].IntheOB,autoﬂuorescentstruc-
tures were observed in tissue from mice that received intra-
nasal saline or MSC-EGFPs, and also from mice that did
not receive any intranasal treatment, suggesting that physical
stress caused by intranasal injections is not the cause of OB
autoﬂourescence. Little is known about autoﬂuorescence in
the OB, but two reports describe naturally occurring lipo-
fuscin in the OB and its relationship to oxidative enzymatic
activity [38, 39].
In an attempt to circumvent autoﬂuorescence, we per-
formed electron microscopy on tissue processed for GFP im-
munoreactivity using DAB as the chromagen. It has previ-
ously been shown at the ultrastructural level that GFP is
found in clusters associated with endoplasmic reticulum
[40–42]. In our study, we did not observe GFP-speciﬁc stain-
ing at the ultrastructural level in tissue taken from the stria-
tum of mice 7 days or 2 months after intranasal delivery of
MSC-EGFPs. Rather, in regions that stained positively for
DAB(seeFigure 5(a)),weobservedmanyexamplesofcellsin
various stages of degradation, including shrunken, electron-
dense necrotic neurons with pyknotic nuclei. This type of
morphology has been described previously [34], and toge-
ther with the high levels of GFAP found around the striatal
injectionsite,isconsistentwiththelikelihoodthatthestriatal
lesion resulted in an inﬂammatory response that triggered
cellular degradation and necrosis, resulting in deposits
of autoﬂuorescent debris (e.g., lipofuscin). Interestingly,
similar structures were not observed in the OB (data not
shown).
The phenotype of MSCs may play a critical role in viabi-
lity after implantation. FACS-based phenotyping is com-
monly used to identify MSC isolated from bone marrow,
but proﬁles and marker selection vary among studies. Thus,
MSCs have been shown to be positive for a range of antigens
including CD44, CD105 (SH2; endoglin), CD106 (VCAM-
1), CD166, CD29, CD73 (SH3 and SH4), CD90 (Thy-1),
CD117, STRO-1, and Sca-1 while lacking expression of he-
matopoietic and endothelial surface molecules, such as
CD11b, CD14, CD31, CD33, CD34, CD133, and CD45
(reviewedin[43]).Inthecurrentstudy,FCMphenotypingof
the MSC-EGFPs at passage 4 in mitogen-containing culture
conditions revealed strong expression of Sca-1, CD29, and
CD44 and no expression of CD106, CD105, CD73, CD45,
and CD11b. To gain further insight into their phenotypic
properties, we compared the MSC-EGFP proﬁle with that
from bone marrow cells (BMCs) cultured using an estab-
lished protocol [30]. In our hands, BMCs cultured for three
weeks in serum-containing mitogen-free media segregated
into two cell populations with diﬀerent expression proﬁles.
A fraction of large cells that were morphologically similar to
MSC-EGFPs and expressed Sca-1 (weak expression), CD29,
a n dC D 4 4 ;af r a c t i o no fs m a l lc e l l st h a tw e r en e g a t i v ef o r
all markers analyzed. These data demonstrate that—des-
pite being derived by established methods—the clonally
expandedMSC-EGFPsusedinthisstudyhadaBMC-derived
phenotype that resembled some characteristics of MSCs
but were clearly not of hematopoietic or ﬁbroblast lineages
[6, 24, 30]. It should be noted that this line of MSC-EGFPs
was used previously in an in vitro diﬀerentiation para-
digm to derive neural cell populations [27]. Together, these
ﬁnding underscore the importance of establishing consistent
standards for deﬁning MSCs and MSC subtypes.
5. Conclusions
In summary, we found no evidence that intranasally deliv-
ered MSC-EGFPs migrated into, or persisted in, the brains of
mice with striatal lesions whereas intrastriatally implantedStem Cells International 11
stem cells survived for at least 7d. Additionally, we observed
a high degree of autoﬂuorescence in the intact OB and the
lesioned striatum that could easily be mistaken for the pres-
ence of EGFP-labeled MSCs. These last observations conﬁrm
past studies demonstrating that many standard techniques
used for tracking GFP ﬂuorescence can produce misleading
artifacts [28, 29] unless appropriate controls are included
and disclosed [28, 29, 35, 37].
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